Previous research has demonstrated that checkpoint blocking cancer immunotherapy works by inhibiting tumor cells with antibodies produced by the checkpoint inhibitor PD-L1, activating the immune system, and infiltrating the tumor with immunoactive T lymphocytes [28]. The gene discussed is CD274; the disease is neoplasm.